• q
Print

News

  • ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine (28 July 2022)

    MPP invites Expressions of Interest (EoI) from potential sublicensees based anywhere in the world for sublicences to manufacture and sell the cabotegravir long-acting injectable in the licensed territory.

    Read More
  • UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries (May 2022)

    GENEVA, SWITZERLAND / AGILITYPR.NEWS / May 20, 2022 / The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and

    Read More
  • IGBA’s Newly Launched CEO Advisory Committee Holds Inaugural Meeting with WTO Director General (May 2022)

    The newly established IGBA CEO Advisory Committee , a forum for generic and biosimilar medicines industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy matters, held its inaugural meeting on

    Read More
  • IGBA establishes a CEO Advisory Committee (February 2022, Committee updated)

    The International Generic and Biosimilar medicines Association (IGBA) announced today that it has established a CEO Advisory Committee composed of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States.

    Read More
  • Generics Industry At The Forefront In War Against COVID-19 In 2021: Generics Bulletin (informa.com) (January 2022)

    As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

    Read More
  • GENEZIS, the Serbian and Montenegrin Generic and Biosimilar Medicines Association, joins IGBA (January 2022)

    IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that GENEZIS has been accepted and welcomed as a new IGBA Associate Member. 

    Read More
  • Vivian Frittelli takes over the position of IGBA Chair (January 2022)

    IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM), is taking over the position of IGBA

    Read More
  • IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access (November 2021)

    Geneva, November 1 st , 2021 –In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The second Global Biosimilars Week

    Read More
  • Global Biosimilars Week: Message of Sudarshan Jain, Chair, IGBA (October 2021)

    Read More
  • Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid (October 2021)

    07 October, Athens, Greece. Health systems have been severely jolted by COVID-19, causing widespread disruption to the provision of health care worldwide. As countries shift to investment in healthcare system recovery and ongoing management of COVID-19, off-patent medicines will be

    Read More
  • Annual Conference Opening Remarks Suzette Kox (October 2021)

    It is my great pleasure and honor to welcome you all to the Joint Annual Conference of Medicines for Europe and IGBA here in Athens under the title Goal 2030: Access For All...

    Read More
  • Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response (July 2021)

    On 7 July 2021, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a (virtual) workshop titled ‘Enabling Manufacturing Capacity in the COVID-19 Pandemic’ with representatives from the leading association bodies representing biotech firms, developing and industrialized countries vaccine

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

Print

Our Mission and Vision

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

Introduction

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)477438729 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site